CorrectSequence Therapeutics Revenue
Biotechnology Research • 
Pudong, Shanghai, China • 1-10 Employees
CorrectSequence Therapeutics revenue & valuation
| Annual revenue | $769,995 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $2,500,000 |
| Total funding | No funding |
Key Contacts at CorrectSequence Therapeutics
Andiely Lu
Board Director
Susan Mou
Chief Executive Officer
Company overview
| Headquarters | No.99, Haike Road, Pudong Distrct, Shanghai, Shanghai 200120, CN |
| Phone number | +8620082025 |
| Website | |
| NAICS | 541714 |
| Founded | 2020 |
| Employees | 1-10 |
| Socials |
CorrectSequence Therapeutics Email Formats
CorrectSequence Therapeutics uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@correctsequence.com), used 75% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@correctsequence.com | 75% |
{first name}.{last name} | john.doe@correctsequence.com | 25% |
About CorrectSequence Therapeutics
CorrectSequence Therapeutics (Correctseq) is a clinical-stage biotech company employing its proprietary transformer base editing (tBE) technology to pioneer next-generation gene editing therapies. Our leading pipeline candidate, CS-101, utilizing innovative base editor targeting HBG, curing β-hemoglobinopathies, has obtained IND approval from the China NMPA. Clinical data demonstrates its superior performance, indicating significant potential for CS-101 to become a best-in-class gene editing therapy for curing patients with β-hemoglobinopathies. Proof-of-concept (POC) data in mice for in vivo pipelines using tBE-editing therapies via lipid nanoparticle (LNP) delivery are available, including targets for metabolic dysfunction and associated diseases. Ex vivo multiplex editing of T cells on multiple targets simultaneously preserved T cell growth and function in vivo compared to non-edited cells, establishing tBE as the ideal gene editing tool for the next-generation cell therapy development. tBE offers significant advantages in controlling off-target effects and enhancing in vivo editing efficiency, making it ideal for both multiplex editing and precise single-target editing. It is compatible with various delivery system, including ex vivo editing in hematopoietic stem cells (HSCs) and T cells, as well as in vivo editing via LNPs or adeno-associated viruses (AAVs). We are developing multiple pipeline programs targeting genetic diseases, metabolic disorders, and cardiovascular diseases. Our focus on biotechnology innovation, research and development underscores our commitment to providing efficient, reliable and safe solution for unmet medical needs.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
CorrectSequence Therapeutics has 3 employees across 3 departments.
Departments
Number of employees
Funding Data
CorrectSequence Therapeutics has never raised funding before.
CorrectSequence Therapeutics Tech Stack
Discover the technologies and tools that power CorrectSequence Therapeutics's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
JavaScript libraries
Reverse proxies
Security
JavaScript libraries
UI frameworks
Miscellaneous
United Kingdom
Australia
Switzerland
Netherlands
GermanyFrequently asked questions
4.8
40,000 users
